ArticleAmerican journal of cancer research
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.
Article in American journal of cancer research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long Non-Coding RNAs as Strategic Molecules to Augment the Radiation Therapy in Esophageal Squamous Cell Carcinoma.International journal of molecular sciences · 2020Pooled it
- A synthetic benzoxazine dimer derivative targets c-Myc to inhibit colorectal cancer progression.Molecular oncology · 2026Article
- Review
- Using machine learning to discover DNA metabolism biomarkers that direct prostate cancer treatment.Scientific reports · 2025Article
- DNA Damage and Chromatin Rearrangement Work Together to Promote Neurodegeneration.Molecular neurobiology · 2025Review
- Cocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair.Pharmaceutics · 2023Article
- Article
- Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma.Biomedicines · 2021Article
- Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.iScience · 2020Article
- Northern lights assay: a versatile method for comprehensive detection of DNA damage.Nucleic acids research · 2018Article
- Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.Oncotarget · 2017Article
- Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.Oncotarget · 2017Article
- Article
- Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.BioMed research international · 2016Review
- Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players.Frontiers in oncology · 2016Review
- Article
- Profile of veliparib and its potential in the treatment of solid tumors.OncoTargets and therapy · 2015Review
- Harnessing of Programmed Necrosis for Fighting against Cancers.Biomolecules & therapeutics · 2014Review
- Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure.BMC cancer · 2014Article
- Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.Molecular cancer therapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PARP inhibitors are emerging as a valuable new drug class in the treatment of cancer. Recent discoveries make a compelling case for the complexity of DNA repair biomarker evaluation and underscore the need to examine at multiple biomarkers in a relational manner. This review updates the current trends in DNA repair biomarker strategies in use for the PARP inhibitors and describes the impact of many DNA repair biomarkers on PARP inhibitor benefit in the cancer clinic.
Identifiers
21968427PMC3180060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.